US OptionsDetailed Quotes

AVIR250516C2500

Watchlist

0.60
0.000.00%

15min DelayClose May 9 16:00 ET

0.00High0.00Low

Atea Pharmaceuticals Stock Discussion

Teddy123

May 7 19:35

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

$Atea Pharmaceuticals (AVIR.US)$
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

Trytosaveabit

May 7 19:18

update

$Atea Pharmaceuticals (AVIR.US)$ Atea Pharma Presents Results From Full Cohort Of Patients Enrolled In Phase 2 Study Evaluating Once-daily Combination Of BEM And RZR For Treatment Of Hepatitis C Virus
Benzinga· 11 mins ago
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen
Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When Co-Administered with Sta...

Trytosaveabit

Apr 23 19:26

Watching

$Atea Pharmaceuticals (AVIR.US)$ Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025! May 7 to 10th

Trytosaveabit

Apr 17 19:10

news

$Atea Pharmaceuticals (AVIR.US)$ Reuters· 4 mins ago
Atea Pharmaceuticals Inc: Authorized Repurchase of up to $25 Mln of Company's Common Stock

Teddy123

Apr 9 19:14

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

$Atea Pharmaceuticals (AVIR.US)$
Breakthrough: Atea's New 8-Week Hepatitis C Treatment Enters Final Trial Stage

Jaguar8

Dec 16, 2024 18:00

NEWS

$Atea Pharmaceuticals (AVIR.US)$
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
Monday, 16th December at 5:00 am
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has engaged Evercore, a global independent investment bank, to identify potentia...

102352692

Dec 4, 2024 23:00

$Atea Pharmaceuticals (AVIR.US)$ good news why drop?? surprise

Coles

Dec 4, 2024 21:08

$Atea Pharmaceuticals (AVIR.US)$ uhh hello 99% success rate

Jaguar8

Nov 16, 2024 00:01

NEWS

$Atea Pharmaceuticals (AVIR.US)$
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Atea Pharmaceuticals (AVIR) presented three posters at AASLD's The Liver Meeting 2024 supporting the combination of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) treatment.
The Phase 2 lead-in cohort showed a 97% SVR12 success rate with an 8-week treatment course.
Key f...

Jaguar8

May 22, 2024 21:56

$Atea Pharmaceuticals (AVIR.US)$
NEWS
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

No comment yet